|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Increased Urinary Albumin Excretion, Endothelial Dysfunction, and Chronic Low-Grade Inflammation in Type 2 Diabetes
Progressive, Interrelated, and Independently Associated With Risk of Death
1 Department of Internal Medicine and Institute for Cardiovascular Research, Vrije Universiteit Medical Centre, Amsterdam, the Netherlands
2 Steno Diabetes Center, Gentofte, Denmark
3 Institute for Research in Extramural Medicine (EMGO Institute), Vrije Universiteit Medical Centre, Amsterdam, the Netherlands
4 Gaubius Laboratory, TNO Prevention and Health, Leiden, the Netherlands
In 328 type 2 diabetic patients followed for 9.0 years (mean), we investigated whether endothelial dysfunction and chronic inflammation (estimated from plasma markers) can explain the association between (micro)albuminuria and mortality. Of the patients, 113 died. Mortality was increased in patients with baseline microalbuminuria or macroalbuminuria (odds ratios as compared with normoalbuminuria, 1.78 [P < 0.05] and 2.86 [P < 0.01]) and in patients with soluble vascular cell adhesion molecule 1 in the third tertile and C-reactive protein in the second and third tertiles (odds ratios as compared with the first tertile, 2.05 [ P < 0.01], and 1.80 [P < 0.05] and 2.92 [ P < 0.01]). These associations were mutually independent. The mean yearly change in urinary albumin excretion was 9.4%; in von Willebrand factor, 8.1%; in tissue-type plasminogen activator, 2.8%; in soluble vascular cell adhesion molecule 1, 5.2%; in soluble E-selectin, -2.3%; in C-reactive protein, 3.8%; and in fibrinogen, 2.3%. The longitudinal development of urinary albumin excretion was significantly and independently determined by baseline levels of and the longitudinal development of BMI, systolic blood pressure, serum creatinine, glycated hemoglobin and plasma von Willebrand factor (baseline only), soluble E-selectin (baseline only), tissue-type plasminogen activator, C-reactive protein, and fibrinogen. The longitudinal developments of markers of endothelial function and inflammation were interrelated. In type 2 diabetes, increased urinary albumin excretion, endothelial dysfunction, and chronic inflammation are interrelated processes that develop in parallel, progress with time, and are strongly and independently associated with risk of death.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. G. Bruce, W. A. Davis, G. P. Casey, S. E. Starkstein, R. M. Clarnette, O. P. Almeida, and T. M.E. Davis Predictors of Cognitive Decline in Older Individuals With Diabetes Diabetes Care, November 1, 2008; 31(11): 2103 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xue, Q. Qian, A. Adaikalakoteswari, N. Rabbani, R. Babaei-Jadidi, and P. J. Thornalley Activation of NF-E2-Related Factor-2 Reverses Biochemical Dysfunction of Endothelial Cells Induced by Hyperglycemia Linked to Vascular Disease Diabetes, October 1, 2008; 57(10): 2809 - 2817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Suliman, M. I. Yilmaz, J. J. Carrero, A. R. Qureshi, M. Saglam, O. M. Ipcioglu, M. Yenicesu, M. Tong, O. Heimburger, P. Barany, et al. Novel Links between the Long Pentraxin 3, Endothelial Dysfunction, and Albuminuria in Early and Advanced Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 976 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Astrup, L. Tarnow, L. Pietraszek, C. G. Schalkwijk, C. D.A. Stehouwer, H.-H. Parving, and P. Rossing Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years: Association with mortality and decline of glomerular filtration rate Diabetes Care, June 1, 2008; 31(6): 1170 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Lund, L. Tarnow, C. D A Stehouwer, C. G Schalkwijk, T. Teerlink, J. Gram, K. Winther, M. Frandsen, U. M Smidt, O. Pedersen, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes Eur. J. Endocrinol., May 1, 2008; 158(5): 631 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jorgensen, I. Heuch, T. Jenssen, and B. K. Jacobsen Association of Albuminuria and Cancer Incidence J. Am. Soc. Nephrol., May 1, 2008; 19(5): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Wang, S. X. Zhang, R. Mott, Y. Chen, R. R. Knapp, W. Cao, and J.-x. Ma Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1166 - F1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Palmer, W. J. Valentine, R. Chen, N. Mehin, S. Gabriel, B. Bregman, and R. A. Rodby A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1216 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Akalin, O. Alatas, and O. Colak Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients Eur. J. Endocrinol., January 1, 2008; 158(1): 47 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Salles, R. Fiszman, C. R.L. Cardoso, and E. S. Muxfeldt Relation of Left Ventricular Hypertrophy With Systemic Inflammation and Endothelial Damage in Resistant Hypertension Hypertension, October 1, 2007; 50(4): 723 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fukui, H. Ose, I. Nakayama, H. Hosoda, M. Asano, M. Kadono, S.-i. Mogami, G. Hasegawa, T. Yoshikawa, and N. Nakamura Association Between Urinary Albumin Excretion and Serum Dehydroepiandrosterone Sulfate Concentrations in Women With Type 2 Diabetes Diabetes Care, July 1, 2007; 30(7): 1886 - 1888. [Full Text] [PDF]
|
|
|
|
|
|
Y. Song, J. E. Manson, L. Tinker, N. Rifai, N. R. Cook, F. B. Hu, G. S. Hotamisligil, P. M. Ridker, B. L. Rodriguez, K. L. Margolis, et al. Circulating Levels of Endothelial Adhesion Molecules and Risk of Diabetes in an Ethnically Diverse Cohort of Women Diabetes, July 1, 2007; 56(7): 1898 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Weir Microalbuminuria and Cardiovascular Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 581 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Kakafika, D. P. Mikhailidis, A. Karagiannis, and V. G. Athyros The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome J. Clin. Pharmacol., May 1, 2007; 47(5): 642 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Juutilainen, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Retinopathy Predicts Cardiovascular Mortality in Type 2 Diabetic Men and Women Diabetes Care, February 1, 2007; 30(2): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Persson, P. Rossing, P. Hovind, C. D.A. Stehouwer, C. Schalkwijk, L. Tarnow, and H.-H. Parving Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy Diabetes, December 1, 2006; 55(12): 3550 - 3555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Luo, M. Chen, Q. Wen, M. Zhao, B. Zhang, X. Li, F. Wang, Q. Huang, C. Yao, T. Jiang, et al. Rapid and Simultaneous Quantification of 4 Urinary Proteins by Piezoelectric Quartz Crystal Microbalance Immunosensor Array Clin. Chem., December 1, 2006; 52(12): 2273 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Hansen, M.-A. Gall, L. Tarnow, S. Thiel, C. D. Stehouwer, C. G. Schalkwijk, H.-H. Parving, and A. Flyvbjerg Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med, October 9, 2006; 166(18): 2007 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D.A. Stehouwer and Y. M. Smulders Microalbuminuria and Risk for Cardiovascular Disease: Analysis of Potential Mechanisms J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2106 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. D. de Mello, T. Zelmanovitz, M. S Perassolo, M. J Azevedo, and J. L Gross Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria Am. J. Clinical Nutrition, May 1, 2006; 83(5): 1032 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. K. de Aguiar, L. R. Bahia, N. Villela, C. Laflor, F. Sicuro, N. Wiernsperger, D. Bottino, and E. Bouskela Metformin Improves Endothelial Vascular Reactivity in First-Degree Relatives of Type 2 Diabetic Patients With Metabolic Syndrome and Normal Glucose Tolerance Diabetes Care, May 1, 2006; 29(5): 1083 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Starkey, S. J. Haidacher, W. S. LeJeune, X. Zhang, B. C. Tieu, S. Choudhary, A. R. Brasier, L. A. Denner, and R. G. Tilton Diabetes-Induced Activation of Canonical and Noncanonical Nuclear Factor-{kappa}B Pathways in Renal Cortex. Diabetes, May 1, 2006; 55(5): 1252 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. de Jager, J. M. Dekker, A. Kooy, P. J. Kostense, G. Nijpels, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 Diabetes: The Hoorn Study Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1086 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Iino, T. Fukui, K. Anzai, M. Iwase, K. Kogawa, M. Ogimoto, J. Ono, T. Asano, M. Iida, and K. Tamura Serum Vitamin C Levels in Type 2 Diabetic Nephropathy Diabetes Care, November 1, 2005; 28(11): 2808 - 2809. [Full Text] [PDF]
|
|
|
|
|
|
E. Magid, H. Guldager, D. Hesse, and M. S. Christiansen Monitoring Urinary Orosomucoid in Acute Inflammation: Observations on Urinary Excretion of Orosomucoid, Albumin, {alpha}1-Microglobulin, and IgG Clin. Chem., November 1, 2005; 51(11): 2052 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation, October 25, 2005; 112(17): 2735 - 2752. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mittermayer, J. Pleiner, G. Schaller, S. Zorn, K. Namiranian, S. Kapiotis, G. Bartel, M. Wolfrum, M. Brugel, J. Thiery, et al. Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1752 - H1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. van Hecke, J. M. Dekker, C. D.A. Stehouwer, B. C.P. Polak, J. H. Fuller, A. K. Sjolie, A. Kofinis, R. Rottiers, M. Porta, and N. Chaturvedi Diabetic Retinopathy Is Associated With Mortality and Cardiovascular Disease Incidence: The EURODIAB Prospective Complications Study Diabetes Care, June 1, 2005; 28(6): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr, P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. Farber, et al. Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, April 25, 2005; 165(8): 936 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
M. Dalla Vestra, M. Mussap, P. Gallina, M. Bruseghin, A. M. Cernigoi, A. Saller, M. Plebani, and P. Fioretto Acute-Phase Markers of Inflammation and Glomerular Structure in Patients with Type 2 Diabetes J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S78 - S82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz Diabetic Nephropathy: Diagnosis, Prevention, and Treatment Diabetes Care, January 1, 2005; 28(1): 164 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schernthaner, D. R. Matthews, B. Charbonnel, M. Hanefeld, P. Brunetti, and on Behalf of the Quarter Study Group Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6068 - 6076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fukui, Y. Kitagawa, N. Nakamura, M. Kadono, G. Hasegawa, and T. Yoshikawa Association Between Urinary Albumin Excretion and Serum Dehydroepiandrosterone Sulfate Concentration in Male Patients With Type 2 Diabetes: A possible link between urinary albumin excretion and cardiovascular disease Diabetes Care, December 1, 2004; 27(12): 2893 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Dyer, P. Greenland, P. Elliott, M. L. Daviglus, G. Claeys, H. Kesteloot, H. Ueshima, J. Stamler, and for the INTERMAP Research Group Evaluation of Measures of Urinary Albumin Excretion in Epidemiologic Studies Am. J. Epidemiol., December 1, 2004; 160(11): 1122 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Dyer, P. Greenland, P. Elliott, M. L. Daviglus, G. Claeys, H. Kesteloot, Q. Chan, H. Ueshima, and J. Stamler Estimating Laboratory Precision of Urinary Albumin Excretion and Other Urinary Measures in the International Study on Macronutrients and Blood Pressure Am. J. Epidemiol., August 1, 2004; 160(3): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Palmer, L. Annemans, S. Roze, M. Lamotte, P. Lapuerta, R. Chen, S. Gabriel, P. Carita, R. A. Rodby, D. de Zeeuw, et al. Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease Diabetes Care, August 1, 2004; 27(8): 1897 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, P. W.F. Wilson, and S. M. Grundy Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk? Circulation, June 15, 2004; 109(23): 2818 - 2825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. A. Stehouwer Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease Nephrol. Dial. Transplant., April 1, 2004; 19(4): 778 - 781. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Lane Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective Am J Physiol Renal Physiol, March 1, 2004; 286(3): F442 - F450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Sommeijer, M. R. MacGillavry, J. C.M. Meijers, A. P. Van Zanten, P. H. Reitsma, and H. T. Cate Anti-Inflammatory and Anticoagulant Effects of Pravastatin in Patients With Type 2 Diabetes Diabetes Care, February 1, 2004; 27(2): 468 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C.B. Tan, W.-S. Chow, S. Tam, R. Bucala, and J. Betteridge Association Between Acute-Phase Reactants and Advanced Glycation End Products in Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 223 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension, November 1, 2003; 42(5): 1050 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, October 28, 2003; 108(17): 2154 - 2169. [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hansen, S. Thiel, S. T. Knudsen, C. H. Gravholt, J. S. Christiansen, C. E. Mogensen, and P. L. Poulsen Elevated Levels of Mannan-Binding Lectin in Patients with Type 1 Diabetes J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4857 - 4861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Palmieri, R. P. Tracy, M. J. Roman, J. E. Liu, L. G. Best, J. N. Bella, D. C. Robbins, B. V. Howard, and R. B. Devereux Relation of Left Ventricular Hypertrophy to Inflammation and Albuminuria in Adults With Type 2 Diabetes: The Strong Heart Study Diabetes Care, October 1, 2003; 26(10): 2764 - 2769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Schram, N. Chaturvedi, C. Schalkwijk, F. Giorgino, P. Ebeling, J. H. Fuller, and C. D. Stehouwer Vascular Risk Factors and Markers of Endothelial Function as Determinants of Inflammatory Markers in Type 1 Diabetes: The EURODIAB Prospective Complications Study Diabetes Care, July 1, 2003; 26(7): 2165 - 2173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli, L. Moye, F. M. Sacks, T. Cole, and G. C. Curhan Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1605 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Perassolo, J. C. Almeida, R. L. Pra, V. D. Mello, A. L. Maia, C. C. Moulin, J. L. Camargo, T. Zelmanovitz, M. J. Azevedo, and J. L. Gross Fatty Acid Composition of Serum Lipid Fractions in Type 2 Diabetic Patients With Microalbuminuria Diabetes Care, March 1, 2003; 26(3): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yano, N. Kitagawa, E. C. Gabazza, K. Morioka, H. Urakawa, T. Tanaka, A. Katsuki, R. Araki-Sasaki, Y. Hori, K. Nakatani, et al. Increased Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels in Normotensive Type 2 Diabetic Patients with Microalbuminuria J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Engstrom, L. Stavenow, B. Hedblad, P. Lind, K.-F. Eriksson, L. Janzon, and F. Lindgarde Inflammation-Sensitive Plasma Proteins, Diabetes, and Mortality and Incidence of Myocardial Infarction and Stroke: A Population-Based Study Diabetes, February 1, 2003; 52(2): 442 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
< |